Announced Sat, 30 May · 19:09 IST

Appointment of Internal Auditor for the year 2026-27

Revenue DeclinePat NegativeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-7.9%1-day move
₹8.50
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-7.9-7.6-6.9-2.4-2.9-5.4-10.8-14.7
Up moveDown movePending
AI summary

Hindustan Bio Sciences Ltd reported a board meeting outcome on May 30, 2026. The company posted a net loss of Rs 7.89 lakhs for FY 2026, compared to a profit of Rs 10.08 lakhs in FY 2025. Revenue from operations declined to Rs 73.71 lakhs from Rs 81.33 lakhs, a drop of about 9.4%. The company also re-appointed Mr. GBK Viswanadham as Internal Auditor for FY 2026-27. Statutory auditors VASG & Associates issued an unmodified opinion on the financial statements. Reserves turned more negative at Rs 122.42 lakhs compared to Rs 114.52 lakhs previously, indicating accumulated losses.

Likely market impact

The company swung to a loss in FY 2026 with declining revenues, which is negative for shareholders. However, the clean audit opinion and appointment of an internal auditor provide some governance comfort. The negative reserves position is a concern.